ArticleFrontiers in medicine2025
Combination of anti-CD20 and hetrombopag in relapsed/refractory immune thrombocytopenia: a case series.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to assess the effectiveness of anti-CD20 monoclonal antibody and hetrombopag for relapsed/refractory immune thrombocytopenia (ITP) following glucocorticoid treatment. Methods: We retrospectively included four patients with relapsed/refractory ITP. The median disease duration is 9 months. Their prior lines of therapy numbered 4, 2, 4, and 2, respectively. They were treated with a combination of anti-CD20 monoclonal antibody and hetrombopag, followed by maintenance therapy with hetrombopag and monitoring of platelet (PLT) changes. Results: All four patients achieved complete response (CR), with the time to response ranging from 2 to 9 days and the duration of response (DoR) ranging from 3 to 27 months. CR was defined as a PLT count >100 × 10 Conclusion: Combining anti-CD20 monoclonal antibody with hetrombopag may offer therapeutic benefits in patients with relapsed/refractory ITP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.